**Chapter 14**

**Pharmacological Therapies**

Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology, 68*(7), 515-521. doi:10.1212/01.wnl.0000253187.66183.9c

Angst, M. S., & Clark, J. D. (2006). Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology, 104*(3), 570-587.

Arnold, L. M., Keck, P. E., & Welge, J. A. (2000). Antidepressant treatment of fibromyalgia. A meta-analysis and review. *Psychosomatics, 41*(2), 104-113.

Backonja, M. M. (2002). Use of anticonvulsants for treatment of neuropathic pain. *Neurology, 59*(5 Suppl 2), S14-17.

Ballantyne, J. C., & Mao, J. (2003). Opioid therapy for chronic pain. *N Engl J Med, 349*(20), 1943-1953. doi:10.1056/NEJMra025411

Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of opioids for chronic paIn a review of the evidence. *Clin J Pain, 24*(6), 469-478. doi:10.1097/AJP.0b013e31816b2f26

Bannwarth, B., & Péhourcq, F. (2003). [Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues]. *Drugs, 63 Spec No 2*, 5-13.

Becker, W. C., Fiellin, D. A., Merrill, J. O., Schulman, B., Finkelstein, R., Olsen, Y., & Busch, S. H. (2008). Opioid use disorder in the United States: insurance status and treatment access. *Drug Alcohol Depend, 94*(1-3), 207-213. doi:10.1016/j.drugalcdep.2007.11.018

Beaulieu P., Lussier, D., Porreca, F., & Dickenson, A.H. (Eds.). (2010). *Pharmacology of Pain*. Seattle, WA:IASP Press.

Biegon, A., & Samuel, D. (1980). Interaction of tricyclic antidepressants with opiate receptors. *Biochem Pharmacol, 29*(3), 460-462.

Breasted, J. (1930). *Ancient records of Egypt.* Vol. 3. Chicago: University of Chicago Oriental Institute Publications.

Brookoff, D. (2000). Chronic paIn 1. A new disease? *Hosp Pract (1995), 35*(7), 45-52, 59.

Broussard, C. S., Rasmussen, S. A., Reefhuis, J., Friedman, J. M., Jann, M. W., Riehle-Colarusso, T., Study, National Birth Defects Prevention. (2011). Maternal treatment with opioid analgesics and risk for birth defects. *Am J Obstet Gynecol, 204*(4), 314.e311-311. doi:10.1016/j.ajog.2010.12.039

Brunton, L.L., Lazo, J.S., Parker, K.L. (Eds.) (2006). *Goodman & Gilman’s The Pharmacological basis of therapeutics*. 11th edition. New York: McGraw-Hill Companies.

Budney, A. J., Roffman, R., Stephens, R. S., & Walker, D. (2007). Marijuana dependence and its treatment. *Addict Sci Clin Pract, 4*(1), 4-16.

Butler, S. F., Black, R. A., Serrano, J. M., Wood, M. E., & Budman, S. H. (2010). Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. *J Opioid Manag, 6*(4), 239-241, 246-252.

Butler, S. F., Black, R., Grimes Serrano, J. M., Folensbee, L., Chang, A., & Katz, N. (2010). Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. *Pain Med, 11*(1), 81-91. doi:10.1111/j.1526-4637.2009.00737.x

Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H., & Coplan, P. M. (2013). Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. *J Pain, 14*(4), 351-358. doi:10.1016/j.jpain.2012.08.008

Carlsson, A., Corrodi, H., Fuxe, K., & Hökfelt, T. (1969). Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. *Eur J Pharmacol, 5*(4), 357-366.

Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health:detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.

Center for Disease Control and Prevention. Wide-ranging Online Data for Epidemiologic Research (WONDER), Multiple-Cause-of-Death file, 2000-2014. 2015. <http://www.cdc.gov/nchs/data/healthpolicy/AADR_US_2000-2014.pdf>

Chang, G., Chen, L., & Mao, J. (2007). Opioid tolerance and hyperalgesia. *Med Clin North Am, 91*(2), 199-211. doi:10.1016/j.mcna.2006.10.003

Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Denisco, R. C., Donaldson, G. W., Weisner, C. M. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. *J Pain, 11*(9), 807-829. doi:10.1016/j.jpain.2010.02.019

Chong, M. S., & Hester, J. (2007). Diabetic painful neuropathy: current and future treatment options. *Drugs, 67*(4), 569-585.

Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., Panel, American Pain Society-American Academy of Pain Medicine Opioids Guidelines. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain, 10*(2), 113-130. doi:10.1016/j.jpain.2008.10.008

Chou, R., Huffman, L. H., Society, American Pain, & Physicians, American College of. (2007). Medications for acute and chronic low back paIn a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. *Ann Intern Med, 147*(7), 505-514.

Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *Clin J Pain, 24*(6), 479-496. doi:10.1097/AJP.0b013e31816b2f43

Cicero, T. J., & Ellis, M. S. (2015). Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. *JAMA Psychiatry, 72*(5), 424-430. doi:10.1001/jamapsychiatry.2014.3043

Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012). Effect of abuse-deterrent formulation of OxyContin. *N Engl J Med, 367*(2), 187-189. doi:10.1056/NEJMc1204141

Clauw, D. J., Mease, P., Palmer, R. H., Gendreau, R. M., & Wang, Y. (2008). Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. *Clin Ther, 30*(11), 1988-2004. doi:10.1016/j.clinthera.2008.11.009

Coderre, T. J., & Melzack, R. (1992). The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. *J Neurosci, 12*(9), 3665-3670.

Cohen, S. (1985). Marijuana and reproductive functions. *Drug Abuse Alcohol News*, *13*(1).

Compton, W. M., Jones, C. M., & Baldwin, G. T. (2016). Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. *N Engl J Med, 374*(2), 154-163. doi:10.1056/NEJMra1508490

Coplan, P. M., Chilcoat, H. D., Butler, S. F., Sellers, E. M., Kadakia, A., Harikrishnan, V., Dart, R. C. (2016). The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. *Clin Pharmacol Ther, 100*(3), 275-286. doi:10.1002/cpt.390

Coplan, P.M., Green, C., Perrin, N., Campbell, C., Severtson, G., Bucher-Bartelson, B., Chilcoat, H., Sessler, N.E., Kale, H., 2013. Poster Session Presented at the Management of Pain, Montreal, Canada, August 25-28 (poster#250).

Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., & Chilcoat, H. D. (2013). Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. *Pharmacoepidemiol Drug Saf, 22*(12), 1274-1282. doi:10.1002/pds.3522

Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ, 184*(10), 1143-1150. doi:10.1503/cmaj.110837

Desai, J. C., Sanyal, S. M., Goo, T., Benson, A. A., Bodian, C. A., Miller, K. M., Aisenberg, J. (2008). Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. *Dig Dis Sci, 53*(8), 2059-2065. doi:10.1007/s10620-007-0127-4

Dick, I. E., Brochu, R. M., Purohit, Y., Kaczorowski, G. J., Martin, W. J., & Priest, B. T. (2007). Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. *J Pain, 8*(4), 315-324. doi:10.1016/j.jpain.2006.10.001

Dixon, W. G., Suissa, S., & Hudson, M. (2011). The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. *Arthritis Res Ther, 13*(4), R139. doi:10.1186/ar3453

Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002). Predictors of infection in rheumatoid arthritis. *Arthritis Rheum, 46*(9), 2294-2300. doi:10.1002/art.10529

du Plessis, S. S., Agarwal, A., & Syriac, A. (2015). Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. *J Assist Reprod Genet, 32*(11), 1575-1588. doi:10.1007/s10815-015-0553-8

Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., Weinstein, S. M. (2003). Advances in neuropathic paIn diagnosis, mechanisms, and treatment recommendations. *Arch Neurol, 60*(11), 1524-1534. doi:10.1001/archneur.60.11.1524

Dworkin, R. H., O'Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Wallace, M. S. (2007). Pharmacologic management of neuropathic paIn evidence-based recommendations. *Pain, 132*(3), 237-251. doi:10.1016/j.pain.2007.08.033

Epidemic: responding to America’s prescription drug abuse crisis. Washington, DC: Office of National Drug Control Policy Executive, Office of the President of the United State, 2011 (<http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf>).

Finnerup, N. B., Otto, M., Jensen, T. S., & Sindrup, S. H. (2007). An evidence-based algorithm for the treatment of neuropathic pain. *MedGenMed, 9*(2), 36.

Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005). Algorithm for neuropathic pain treatment: an evidence based proposal. *Pain, 118*(3), 289-305. doi:10.1016/j.pain.2005.08.013

Fishbain, D. A., Cole, B., Lewis, J., Rosomoff, H. L., & Rosomoff, R. S. (2008). What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. *Pain Med, 9*(4), 444-459. doi:10.1111/j.1526-4637.2007.00370.x

Fishbain, D. A., Rosomoff, H. L., & Rosomoff, R. S. (1992). Drug abuse, dependence, and addiction in chronic pain patients. *Clin J Pain, 8*(2), 77-85.

Fleming, M. F., Balousek, S. L., Klessig, C. L., Mundt, M. P., & Brown, D. D. (2007). Substance use disorders in a primary care sample receiving daily opioid therapy. *J Pain, 8*(7), 573-582. doi:10.1016/j.jpain.2007.02.432

Food and Drug Administration. (2011). Prescription drug products containing acetaminophen; actions to reduce liver injury from unintentional overdose. *Federal Register*, *76*(10), 2691-2697.

Friedewald, V. E., Bennett, J. S., Christo, J. P., Pool, J. L., Scheiman, J. M., Simon, L. S., Roberts, W. C. (2010). AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. *Am J Cardiol, 106*(6), 873-884. doi:10.1016/j.amjcard.2010.04.006

Fries, J. F., Williams, C. A., Bloch, D. A., & Michel, B. A. (1991). Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. *Am J Med, 91*(3), 213-222.

Furlan, A. D., Sandoval, J. A., Mailis-Gagnon, A., & Tunks, E. (2006). Opioids for chronic noncancer paIn a meta-analysis of effectiveness and side effects. *CMAJ, 174*(11), 1589-1594. doi:10.1503/cmaj.051528

Garner, S., Fidan, D., Frankish, R., Judd, M., Shea, B., Towheed, T., Tugwell, P. (2002). Celecoxib for rheumatoid arthritis. *Cochrane Database Syst Rev*(4), CD003831. doi:10.1002/14651858.CD003831

Giordano, J. (2005). The neurobiology of nociceptive and anti-nociceptive systems. *Pain physician*, *8*(3), 277-90.

Graham, G. G., & Scott, K. F. (2005). Mechanism of action of paracetamol. *Am J Ther, 12*(1), 46-55.

Grant, I., Atkinson, J. H., Gouaux, B., & Wilsey, B. (2012). Medical marijuana: clearing away the smoke. *Open Neurol J, 6*, 18-25. doi:10.2174/1874205X01206010018

Hall, H., & Ogren, S. O. (1981). Effects of antidepressant drugs on different receptors in the brain. *Eur J Pharmacol, 70*(3), 393-407.

Han, W., Ide, S., Sora, I., Yamamoto, H., & Ikeda, K. (2004). A possible genetic mechanism underlying individual and interstrain differences in opioid actions: focus on the mu opioid receptor gene. *Ann N Y Acad Sci, 1025*, 370-375. doi:10.1196/annals.1307.045

Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Grant, B. F. (2016). Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Am J Psychiatry, 173*(6), 588-599. doi:10.1176/appi.ajp.2015.15070907

Hill, K. P. (2015). Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA, 313*(24), 2474-2483. doi:10.1001/jama.2015.6199

Isenberg, K. E., & Cicero, T. J. (1984). Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. *Eur J Pharmacol, 103*(1-2), 57-63.

Jensen, B., Chen, J., Furnish, T., & Wallace, M. (2015). Medical Marijuana and Chronic PaIn a Review of Basic Science and Clinical Evidence. *Curr Pain Headache Rep, 19*(10), 50. doi:10.1007/s11916-015-0524-x

Jensen, T. S., Madsen, C. S., & Finnerup, N. B. (2009). Pharmacology and treatment of neuropathic pains. *Curr Opin Neurol, 22*(5), 467-474. doi:10.1097/WCO.0b013e3283311e13

Jones, R. T., Benowitz, N. L., & Herning, R. I. (1981). Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol, 21*(8-9 Suppl), 143S-152S.

Kahan, M., Srivastava, A., Spithoff, S., & Bromley, L. (2014). Prescribing smoked cannabis for chronic noncancer paIn preliminary recommendations. *Can Fam Physician, 60*(12), 1083-1090.

Katz, N. P., Adams, E. H., Benneyan, J. C., Birnbaum, H. G., Budman, S. H., Buzzeo, R. W., Lande, S. D. (2007). Foundations of opioid risk management. *Clin J Pain, 23*(2), 103-118. doi:10.1097/01.ajp.0000210953.86255.8f

Kehlet, H., & Dahl, J. B. (1993). The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. *Anesth Analg, 77*(5), 1048-1056.

Kellogg, A., Rose, C. H., Harms, R. H., & Watson, W. J. (2011). Current trends in narcotic use in pregnancy and neonatal outcomes. *Am J Obstet Gynecol, 204*(3), 259.e251-254. doi:10.1016/j.ajog.2010.12.050

Kimishima, A., Wenthur, C. J., Zhou, B., & Janda, K. D. (2017). An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life. *ACS Chem Biol, 12*(1), 36-40. doi:10.1021/acschembio.6b00977

Kleber, H. D., & DuPont, R. L. (2012). Physicians and medical marijuana. *Am J Psychiatry, 169*(6), 564-568. doi:10.1176/appi.ajp.2012.12030373

Kourbeti, I. S., Ziakas, P. D., & Mylonakis, E. (2014). Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. *Clin Infect Dis, 58*(12), 1649-1657. doi:10.1093/cid/ciu185

Lindley, D. A. Muscle relaxants in pain. In Sinatra, R.S., Jahr, J. S., Watkins-Pithford, M. W. (Eds.). (2011). *The essence of analgesia and analgesics*. New York: Cambridge University Press, pp 360-365.

Listing, J., Gerhold, K., & Zink, A. (2013). The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatology (Oxford), 52*(1), 53-61. doi:10.1093/rheumatology/kes305

Lorenz, K. A., Lynn, J., Dy, S. M., Shugarman, L. R., Wilkinson, A., Mularski, R. A., Shekelle, P. G. (2008). Evidence for improving palliative care at the end of life: a systematic review. *Ann Intern Med, 148*(2), 147-159.

Low, P. A., Opfer-Gehrking, T. L., Dyck, P. J., Litchy, W. J., & O'Brien, P. C. (1995). Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. *Pain, 62*(2), 163-168.

Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev*(1), CD007115. doi:10.1002/14651858.CD007115.pub3

Lynch, M. E., & Ware, M. A. (2015). Cannabinoids for the Treatment of Chronic Non-Cancer PaIn An Updated Systematic Review of Randomized Controlled Trials. *J Neuroimmune Pharmacol, 10*(2), 293-301. doi:10.1007/s11481-015-9600-6

Majithia, N., Smith, T. J., Coyne, P. J., Abdi, S., Pachman, D. R., Lachance, D., Loprinzi, C. L. (2016). Scrambler Therapy for the management of chronic pain. *Support Care Cancer, 24*(6), 2807-2814. doi:10.1007/s00520-016-3177-3

Manchikanti, L., Abdi, S., Atluri, S., Balog, C. C., Benyamin, R. M., Boswell, M. V., Physicians, American Society of Interventional Pain. (2012). American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer paIn Part I--evidence assessment. *Pain Physician, 15*(3 Suppl), S1-65.

Manchikanti, L., Helm, S., Fellows, B., Janata, J. W., Pampati, V., Grider, J. S., & Boswell, M. V. (2012). Opioid epidemic in the United States. *Pain Physician, 15*(3 Suppl), ES9-38.

Manchikanti, L., Kaye, A. M., Knezevic, N. N., McAnally, H., Slavin, K., Trescot, A. M., Hirsch, J. A. (2017). Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer PaIn American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician, 20*(2S), S3-S92.

Marinangeli, F., Ciccozzi, A., Leonardis, M., Aloisio, L., Mazzei, A., Paladini, A., Varrassi, G. (2004). Use of strong opioids in advanced cancer paIn a randomized trial. *J Pain Symptom Manage, 27*(5), 409-416. doi:10.1016/j.jpainsymman.2003.10.006

Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014). Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev*(12), CD008940. doi:10.1002/14651858.CD008940.pub2

Martell, B. A., O'Connor, P. G., Kerns, R. D., Becker, W. C., Morales, K. H., Kosten, T. R., & Fiellin, D. A. (2007). Systematic review: opioid treatment for chronic back paIn prevalence, efficacy, and association with addiction. *Ann Intern Med, 146*(2), 116-127.

Martucci, C., Panerai, A. E., & Sacerdote, P. (2004). Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. *Pain*, *110*(1), 385-392.

Max, M. B., Culnane, M., Schafer, S. C., Gracely, R. H., Walther, D. J., Smoller, B., & Dubner, R. (1987). Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology, 37*(4), 589-596.

Max, M. B., Kishore-Kumar, R., Schafer, S. C., Meister, B., Gracely, R. H., Smoller, B., & Dubner, R. (1991). Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. *Pain, 45*(1), 3-9; discussion 1-2.

Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., & Dubner, R. (1992). Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med, 326*(19), 1250-1256. doi:10.1056/NEJM199205073261904

Mease, P. J., Clauw, D. J., Gendreau, R. M., Rao, S. G., Kranzler, J., Chen, W., & Palmer, R. H. (2009). The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. *J Rheumatol, 36*(2), 398-409. doi:10.3899/jrheum.080734

Miller, M., Stürmer, T., Azrael, D., Levin, R., & Solomon, D. H. (2011). Opioid analgesics and the risk of fractures in older adults with arthritis. *J Am Geriatr Soc, 59*(3), 430-438. doi:10.1111/j.1532-5415.2011.03318.x

Moore, R. A., & McQuay, H. J. (2005). Prevalence of opioid adverse events in chronic non-malignant paIn systematic review of randomised trials of oral opioids. *Arthritis Res Ther, 7*(5), R1046-1051. doi:10.1186/ar1782

Moore, R. A., Straube, S., Wiffen, P. J., Derry, S., & McQuay, H. J. (2009). Pregabalin for acute and chronic pain in adults. *Cochrane Database Syst Rev*(3), CD007076. doi:10.1002/14651858.CD007076.pub2

Munsterhjelm, E., Munsterhjelm, N. M., Niemi, T. T., Ylikorkala, O., Neuvonen, P. J., & Rosenberg, P. H. (2005). Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. *Anesthesiology, 103*(4), 712-717.

Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., & Schoelles, K. M. (2010). Long-term opioid management for chronic noncancer pain. *Cochrane Database Syst Rev*, *1*(1).

Onur, M, & Benzon, H.T. (1999). Muscle relaxants. In *Essentials of pain medicine and regional anesthesia*. New York: Churchill Livingstone, pp 78-82.

Paice, J. A., Ferrans, C. E., Lashley, F. R., Shott, S., Vizgirda, V., & Pitrak, D. (2000). Topical capsaicin in the management of HIV-associated peripheral neuropathy. *J Pain Symptom Manage, 19*(1), 45-52.

Paulozzi, L. J. (2012). Prescription drug overdoses: a review. *J Safety Res, 43*(4), 283-289. doi:10.1016/j.jsr.2012.08.009

Pergolizzi, J., Böger, R. H., Budd, K., Dahan, A., Erdine, S., Hans, G., Sacerdote, P. (2008). Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). *Pain Pract, 8*(4), 287-313. doi:10.1111/j.1533-2500.2008.00204.x

Pert, C. B., & Snyder, S. H. (1973). Opiate receptor: demonstration in nervous tissue. *Science, 179*(4077), 1011-1014.

Pertwee, R. G. (2007). Cannabinoids and multiple sclerosis. *Mol Neurobiol, 36*(1), 45-59. doi:10.1007/s12035-007-0005-2

Portenoy, R.K. MM. Adjuvant analgesics. In McCaffery, M. PC (Ed.) (1999). *Pain clinical manual*, 2nd Edition. St. Louis. MO: Mosby Inc.

Potter, D., & Edwards, K. R. (1998). Potential role of topiramate in relief of neuropathic pain. *Neurology*, *50*(4), A255.

Pravetoni, M. (2016). Biologics to treat substance use disorders: Current status and new directions. *Hum Vaccin Immunother, 12*(12), 3005-3019. doi:10.1080/21645515.2016.1212785

Rajagopal, A., Vassilopoulou-Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2003). Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. *J Pain Symptom Manage, 26*(5), 1055-1061.

Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2016). *Mil Med, 181*(5), 397-399. doi:10.7205/MILMED-D-16-00012

Reynolds, I. J., & Miller, R. J. (1988). Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. *Br J Pharmacol, 95*(1), 95-102.

Riley, J. L., & Hastie, B. A. (2008). Individual differences in opioid efficacy for chronic noncancer pain. *Clin J Pain, 24*(6), 509-520. doi:10.1097/AJP.0b013e31816c6654

Roelofs, P. D., Deyo, R. A., Koes, B. W., Scholten, R. J., & van Tulder, M. W. (2008). Non-steroidal anti-inflammatory drugs for low back pain. *Cochrane Database Syst Rev*(1), CD000396. doi:10.1002/14651858.CD000396.pub3

Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag, 4*(1), 245-259.

Saunders, K. W., Dunn, K. M., Merrill, J. O., Sullivan, M., Weisner, C., Braden, J. B., Von Korff, M. (2010). Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med, 25*(4), 310-315. doi:10.1007/s11606-009-1218-z

Schattner, A. (2014). Review: bDMARDs are linked to increased risk for infection compared with conventional synthetic DMARDs in RA. *Ann Intern Med, 161*(12), JC9. doi:10.7326/0003-4819-161-12-201412160-02009

Schug, S. A. (2006). The role of COX-2 inhibitors in the treatment of postoperative pain. *J Cardiovasc Pharmacol, 47 Suppl 1*, S82-86.

See, S., & Ginzburg R. (2008). Skeletal muscle relaxants. *Pharmacotherapy*, *28*:207-213.

Shaheen, N. J. (2006). The rise and fall (and rise?) of endoscopic anti-reflux procedures. *Gastroenterology, 131*(3), 952-954. doi:10.1053/j.gastro.2006.07.030

Simon, O., & Yelnik, A. P. (2010). Managing spasticity with drugs. *Eur J Phys Rehabil Med, 46*(3), 401-410.

Sindrup, S. H., & Jensen, T. S. (1999). Efficacy of pharmacological treatments of neuropathic paIn an update and effect related to mechanism of drug action. *Pain, 83*(3), 389-400.

Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S. (2005). Antidepressants in the treatment of neuropathic pain. *Basic Clin Pharmacol Toxicol, 96*(6), 399-409. doi:10.1111/j.1742-7843.2005.pto\_96696601.x

Smith, H. S., Harris, R., & Clauw, D. (2011). Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. *Pain Physician, 14*(2), E217-245.

Society, A. P. (2000). Pain assessment and treatment in the managed care environment. *The Case Manager*, *11*(5), 50-53.

Subcommittee, P. D. A. (2013). Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities.

Takkouche, B., Montes-Martínez, A., Gill, S. S., & Etminan, M. (2007). Psychotropic medications and the risk of fracture: a meta-analysis. *Drug Saf, 30*(2), 171-184.

Tannenbaum, H., Bombardier, C., Davis, P., Russell, A. S., & Group, Third Canadian Consensus Conference. (2006). An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. *J Rheumatol, 33*(1), 140-157.

Thomas, R. J. (1995). Excitatory amino acids in health and disease. *J Am Geriatr Soc, 43*(11), 1279-1289.

Toth, P. P., & Urtis, J. (2004). Commonly used muscle relaxant therapies for acute low back paIn a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. *Clin Ther, 26*(9), 1355-1367. doi:10.1016/j.clinthera.2004.09.008

Unick, G., Rosenblum, D., Mars, S., & Ciccarone, D. (2014). The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. *Addiction, 109*(11), 1889-1898. doi:10.1111/add.12664

Vorobeychik, Y., Chen, L., Bush, M. C., & Mao, J. (2008). Improved opioid analgesic effect following opioid dose reduction. *Pain Med, 9*(6), 724-727. doi:10.1111/j.1526-4637.2008.00501.x

Waldman, H. J. (1994). Centrally acting skeletal muscle relaxants and associated drugs. *Journal of pain and symptom management*, *9*(7), 434-441.

Ware, M. A., & Tawfik, V. L. (2005). Safety issues concerning the medical use of cannabis and cannabinoids. *Pain Res Manag, 10 Suppl A*, 31A-37A.

Wasson, N. J., Varley, C. D., Schwab, P., Fu, R., & Winthrop, K. L. (2013). "Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study". *BMC Infect Dis, 13*, 533. doi:10.1186/1471-2334-13-533

Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med, 6*(6), 432-442. doi:10.1111/j.1526-4637.2005.00072.x

Weinstein, S. M., Shi, M., Buckley, B. J., & Kwarcinski, M. A. (2006). Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. *Clin Ther, 28*(1), 86-98. doi:10.1016/j.clinthera.2006.01.010

Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA, 313*(24), 2456-2473. doi:10.1001/jama.2015.6358

Wiese, A. D., Griffin, M. R., Stein, C. M., Mitchel, E. F., & Grijalva, C. G. (2016). Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. *Arthritis Rheumatol, 68*(2), 323-331. doi:10.1002/art.39462

Wiffen, P. J., McQuay, H. J., Edwards, J., & Moore, R. A. (2011). WITHDRAWN: Gabapentin for acute and chronic pain. *Cochrane Database Syst Rev*(3), CD005452. doi:10.1002/14651858.CD005452.pub2

Williams, B. D., & Buvanendran, A. Multimodal analgesia (sites of analgesic activity). In Sinatra, R.S., Jahr, J.S., & Watkins-Pitchford, J.M. (Eds.). (2011). *The essence of analgesia and analgesics.* Cambridge: Cambridge University Press, pp 57-65.

Williams, B. S., & Christo, P.J. Antipyretic analgesics: Nonsteroidals, acetaminophen and phenazone derivatives. In Manchikanti, L., Christo, P.J., Trescot, A., & Falco, F. J. E. (Eds.). (2011). Foundations of pain medicine and interventional pain management: A comprehensive review. Paducah, KY: American Society of Interventional Pain Physicians.

Winthrop, K. L. (2006). Serious infections with antirheumatic therapy: are biologicals worse? *Ann Rheum Dis, 65 Suppl 3*, iii54-57. doi:10.1136/ard.2006.058503

Wirz, S., Wartenberg, H. C., Elsen, C., Wittmann, M., Diederichs, M., & Nadstawek, J. (2006). Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial. *Clin J Pain, 22*(9), 770-775. doi:10.1097/01.ajp.0000210925.33783.4d

Yaksh, T. L. (1981). Spinal opiate analgesia: characteristics and principles of action. *Pain, 11*(3), 293-346.

Zakrzewska, J. M., & Patsalos, P. N. (1989). Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. *J Neurol Neurosurg Psychiatry, 52*(4), 472-476.